Talphera sells DSUVIA/DZUVEO royalty rights to XOMA for $8M upfront

TALPHERA, INC.

Sold rights to royalty and milestone payments from Vertical Pharma to XOMA for $8M cash.
Potential milestones up to $116.5M based on net sales; Talphera retains partial rights after stepdown.
Stepdown occurs when XOMA receives a minimum payment amount; specific amount not disclosed.
After stepdown: Talphera keeps 50% of DoD sales royalties and milestones; XOMA gets 100% non-DoD.
Agreement includes customary reps, warranties, and indemnification obligations.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

TALPHERA, INC. entered into Payment Interest Purchase Agreement with XOMA (US) LLC valued at $8 million (effective 2024-01-12).

Action: entry
Agreement: asset purchase
Counterparty: XOMA (US) LLC
Value: $8 million
Effective: 2024-01-12

Exact text from the filing

On January 12, 2024, Talphera, Inc. (the “Company”) and XOMA (US) LLC (“XOMA”) entered into a Payment Interest Purchase Agreement (the “Purchase Agreement”) for the sale by the Company to XOMA, in exchange for $8 million, of the Company’s right, title and interest in and to certain amounts payable to the Company (collectively, the “Purchased Receivables”)

View on SEC.gov

Browse all material agreements →

TALPHERA, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-001579

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.